Metabolic HealthSIGNATURENCT07255807
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
A study testing Physical Inactivity and Hypercaloric High-Fat Diet in people with Metabolic Health and Insulin Sensitivity/Resistance, run by University of Copenhagen at 1 site in Denmark.
Trial summary
The goal of this intervention study is to learn more about what causes insulin resistance in otherwise healthy adults, and how short-term changes in physical activity or diet may influence it. The study includes healthy male and female participants aged 25 to 55 years, who meet specific health criteria. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Health, Insulin Sensitivity/Resistance
- What is being tested?
- Physical Inactivity and Hypercaloric High-Fat Diet
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteDenmark
- Study dates
- 9 Jan 2026to 30 Jun 2038
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 25-55 years
- Body Mass Index (BMI): 18-30 kg/m²
- Healthy (no diagnosed chronic diseases)
- Able and willing to comply with study procedures
Who cannot join
- Smoking or nicotine use, current or within the past 5 years
- Alcohol intake exceeding 10 units per week
- Hemoglobin A1c (HbA1c) > 48 mmol/mol (indicative of diabetes or prediabetes)
- Chronic diseases (e.g., cardiovascular disease, diabetes, etc.)
- Chronic medication use, including hormonal treatments
- High physical activity levels (more than 3 hours per week of moderate to vigorous exercise)
Show all 10Show fewer
- Pregnancy or within 3 months postpartum
- Breastfeeding or within 3 months of cessation
- Abnormal routine blood markers (as defined in lab screening)
- Blood donation within the past 2 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
August Krogh Building
Copenhagen, 2100
Kate A Wickham, Ph.D., +45 30638013, kawi@nexs.ku.dk
About this study
Official title: sIgnatuRe: Defining the Human Insulin Resistance Molecular Network
The goal of this intervention study is to learn more about what causes insulin resistance in otherwise healthy adults, and how short-term changes in physical activity or diet may influence it. The study includes healthy male and female participants aged 25 to 55 years, who meet specific health criteria.
The main questions it aims to answer are:
Read more
Does the cause of insulin resistance vary between individuals due to their genes and lifestyle?
Can the investigators identify different types (sub-phenotypes) of insulin resistance at the molecular level?
Researchers will compare groups who either reduce their physical activity for 14 days or consume a high-fat diet for 3 days, to see how these changes affect insulin sensitivity and related biological markers.
Participants will:
- Complete a health screening and be assessed for eligibility
- Undergo baseline testing to measure insulin sensitivity, physical activity, diet, and metabolic health
- Be randomly assigned to one of two short-term interventions (14 days of reduced physical activity, or 3 days of a high-fat, high-calorie diet)
- Repeat selected tests after the intervention to assess changes
This study will help researchers better understand how lifestyle and biology interact in the development of insulin resistance, even in people who are otherwise healthy.
Read the detailed description
This intervention study aims to uncover the molecular mechanisms that underlie insulin resistance in otherwise healthy adults and to explore how short-term lifestyle changes may influence these mechanisms. Insulin resistance is a key feature in the development of type 2 diabetes and other metabolic diseases, but it does not arise uniformly across individuals. The overarching hypothesis is that insulin resistance has multiple underlying causes that differ between individuals, depending on genetic variation and modifiable lifestyle factors such as physical activity and diet.
A total of 80 healthy participants-40 males and 40 females aged between 25 and 55 years-will be recruited. All participants must have a body mass index (BMI) between 18 and 30 and meet strict inclusion and exclusion criteria to minimize confounding variables. Participants will be free of chronic disease, non-smokers, have limited alcohol intake, and not engage in high levels of physical activity. This controlled approach ensures a more accurate assessment of the variables under investigation.
At baseline, all participants will undergo comprehensive phenotyping, including assessments of habitual physical activity, dietary intake, glucose tolerance, and whole-body insulin sensitivity. This will allow the researchers to categorize sub-phenotypes of insulin resistance at both the physiological and molecular level.
Following baseline testing, 40 of the 80 participants will undergo one of two short-term interventions designed to stress metabolic pathways associated with insulin sensitivity:
- Reduced physical activity: Participants will significantly decrease their daily physical activity for 14 days.
- High-fat diet: Participants will consume a hypercaloric high-fat diet for 3 consecutive days.
The aim of these interventions is to test how short-term negative lifestyle changes impact insulin action and related molecular markers, and whether these responses vary between individuals with different phenotypic and genetic profiles.
After the intervention period, selected metabolic tests will be repeated to assess changes in insulin sensitivity and molecular signaling. The primary outcome measure is whole-body insulin action, assessed using gold-standard physiological methods. Exploratory outcomes include identifying cellular and molecular mechanisms contributing to insulin resistance, and understanding the interaction between gene expression and lifestyle responses.
By combining deep phenotyping with short-term interventions, this study will generate new insights into the biological diversity of insulin resistance. Ultimately, this may contribute to the development of more individualized strategies for the prevention and treatment of metabolic diseases.
- Conditions
- Metabolic Health, Insulin Sensitivity/Resistance
- Being tested
- Physical Inactivity, Hypercaloric High-Fat Diet
- Keywords
- Insulin Resistance, Metabolic Health, Glucose Metabolism, Lifestyle Interventions, Physical Inactivity, High-Fat Diet, Molecular Mechanisms, Insulin Sensitivity, Metabolic Phenotyping, Human Intervention Study
- Medical subject headings
- Insulin Resistance, Sedentary Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Physical InactivityBehavioural
Also called Reduced Activity
Participants assigned to the physical inactivity intervention will reduce their daily physical activity to fewer than 1,500 steps per day for 14 consecutive days. This strict limitation significantly decreases overall movement and muscle activity, mimicking a sedentary lifestyle. The aim is to assess the short-term effects of reduced physical activity on insulin sensitivity and related metabolic processes. Compliance will be monitored using activity trackers and daily logs. Baseline metabolic and physiological assessments will be repeated after the intervention to evaluate changes.
Hypercaloric High-Fat DietBehavioural
Also called Overeating
Participants assigned to the high-fat diet intervention will consume a hypercaloric diet rich in fat for 3 consecutive days. The diet is designed to significantly increase caloric intake and fat consumption beyond habitual levels to induce short-term metabolic stress. This intervention aims to assess how a brief period of high-fat overfeeding affects insulin sensitivity and related molecular pathways. Participants' dietary intake will be carefully controlled and monitored to ensure adherence. Baseline metabolic and physiological assessments will be repeated after the intervention to evaluate changes.
| Study group | Role | What they receive |
|---|---|---|
| Baseline Characterization | No intervention | All participants (N=80) undergo extensive baseline characterization over three study visits. This includes assessments of insulin sensitivity, glucose tolerance, metabolic and physiological phenotyping, habitual physical activity, and dietary intake. No intervention is applied during this phase; the purpose is to establish baseline measures and characterize individual variation in insulin resistance and metabolic profiles. Participants complete detailed clinical, physiological, and behavioral assessments without any experimental manipulation. This includes: * Measurement of insulin action and glucose tolerance * Dietary and physical activity profiling * Collection of biospecimens for molecular analyses |
| Lifestyle Interventions | Experimental | A subset of 40 participants are randomized into one of two experimental interventions following baseline assessment:
* 14 days of reduced physical activity (<1,500 steps/day), or
* 3 days of a hypercaloric high-fat diet
The aim is to evaluate how short-term lifestyle stressors affect insulin sensitivity and related molecular markers. Assessments from visits 4 and 5 are compared to baseline to determine within-subject changes.
Intervention Names:
1. Reduced Physical Activity
- Participants limit daily steps to <1,500 for 14 days
2. High-Fat Diet
* Participants consume a hypercaloric, high-fat diet for 3 days
Description of Intervention:
Participants undergo one of the two lifestyle interventions with strict monitoring and support. Selected baseline tests are repeated post-intervention to evaluate metabolic and molecular responses. Receives: Behavioral: Physical Inactivity; Behavioral: Hypercaloric High-Fat Diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Whole-body insulin action
Glucose disposal rates during hyperinsulinemic euglycemic conditions as a marker of whole-body insulin action
Measured: Baseline characterization & immediately following intervention (either 14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Secondary outcomes (3)
Identification of proteins and posttranslational modification of proteins in blood as well as skeletal muscle and adipose tissue biopsies
The obtained samples will be subjected to mass spectrometry-based proteomic and phosphoproteomic analyses. These measurements show protein abundance and posttranslational modifications that regulates protein function. Ultimately, revealing the signaling network underlying the interventions studied. Unit of measure is log2-transformed arbitrary units.
Measured: Baseline & immediately following the intervention (14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Whole-Body Glucose Tolerance
Whole-body glucose tolerance will be assessed by an oral glucose tolerance test (OGTT). Blood glucose and insulin concentrations will be measured at multiple time points following oral glucose ingestion to determine glucose and insulin responses. Glucose and insulin areas under the curve (AUC) values will be used to evaluate changes in glucose tolerance.
Measured: Baseline
Beta Cell Function
Beta cell function will be evaluated using an intravenous glucose tolerance test (IVGTT). Following intravenous glucose administration, arterial glucose and insulin concentrations will be measured at multiple time points to assess first-phase insulin secretion and beta cell responsiveness.
Measured: Baseline & immediately following the intervention (14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start9 Jan 2026
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2038 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic HealthStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study uses a parallel design involving 80 healthy participants who all undergo comprehensive baseline assessments, including physiological and metabolic phenotyping, habitual physical activity, and dietary intake evaluations. Following baseline characterization, 40 participants are assigned to one of two independent intervention arms: 14 days of reduced physical activity or 3 days of a hypercaloric high-fat diet. Each intervention group is studied in parallel, with outcomes compared to assess the specific effects on insulin sensitivity and molecular mechanisms. The parallel design was chosen due to the invasive and time-intensive nature of the interventions and testing procedures, making a crossover design impractical and burdensome for participants.
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- University of Sydney, Queen Mary University of London, Novo Nordisk A/S
- Responsible party
- Principal investigator, Jorgen FP Wojtaszewski, University of Copenhagen
- Investigators
- Jørgen F.P. Wojtaszewski, Ph.D., Principal investigator, University of CopenhagenYlva Hellsten, Ph.D., Principal investigator, University of CopenhagenHenriette Pilegaard, Ph.D., Principal investigator, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07255807
- Sponsor's protocol ID
- SIGNATURE
- Other IDs
- NNF24OC0085866
- Acronym
- SIGNATURE
- Status last verified
- Nov 2025
- First submitted
- 6 Aug 2025
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Due to the sensitive nature of the physiological and molecular data collected, and the relatively small and deeply phenotyped cohort, there is a risk of re-identification. Participants have not provided explicit consent for public sharing of their individual data. Furthermore, data protection regulations under the EU General Data Protection Regulation (GDPR) place strict limitations on the sharing of personal data, particularly when it concerns health-related information. For these reasons, individual participant data will not be shared publicly. Data sharing may be considered in the future under controlled access with appropriate ethical approvals and data use agreements.
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- sIgnatuRe: Defining the Human Insulin Resistance Molecular Network
- ClinicalTrials.gov ID
- NCT07255807
- Acronym / sponsor ID
- SIGNATURE / SIGNATURE
- Conditions
- Metabolic Health, Insulin Sensitivity/Resistance
- Keywords
- Insulin Resistance, Metabolic Health, Glucose Metabolism, Lifestyle Interventions, Physical Inactivity, High-Fat Diet, Molecular Mechanisms, Insulin Sensitivity
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Collaborators
- University of Sydney, Queen Mary University of London, Novo Nordisk A/S
- Study start
- 9 Jan 2026 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2038 (estimated)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this intervention study is to learn more about what causes insulin resistance in otherwise healthy adults, and how short-term changes in physical activity or diet may influence it. The study includes healthy male and female participants aged 25 to 55 years, who meet specific health criteria.
The main questions it aims to answer are:
Does the cause of insulin resistance vary between individuals due to their genes and lifestyle?
Can the investigators identify different types (sub-phenotypes) of insulin resistance at the molecular level?
Researchers will compare groups who either reduce their physical activity for 14 days or consume a high-fat diet for 3 days, to see how these changes affect insulin sensitivity and related biological markers.
Participants will:
- Complete a health screening and be assessed for eligibility
- Undergo baseline testing to measure insulin sensitivity, physical activity, diet, and metabolic health
- Be randomly assigned to one of two short-term interventions (14 days of reduced physical activity, or 3 days of a high-fat, high-calorie diet)
- Repeat selected tests after the intervention to assess changes
This study will help researchers better understand how lifestyle and biology interact in the development of insulin resistance, even in people who are otherwise healthy.
Detailed description
This intervention study aims to uncover the molecular mechanisms that underlie insulin resistance in otherwise healthy adults and to explore how short-term lifestyle changes may influence these mechanisms. Insulin resistance is a key feature in the development of type 2 diabetes and other metabolic diseases, but it does not arise uniformly across individuals. The overarching hypothesis is that insulin resistance has multiple underlying causes that differ between individuals, depending on genetic variation and modifiable lifestyle factors such as physical activity and diet.
A total of 80 healthy participants-40 males and 40 females aged between 25 and 55 years-will be recruited. All participants must have a body mass index (BMI) between 18 and 30 and meet strict inclusion and exclusion criteria to minimize confounding variables. Participants will be free of chronic disease, non-smokers, have limited alcohol intake, and not engage in high levels of physical activity. This controlled approach ensures a more accurate assessment of the variables under investigation.
At baseline, all participants will undergo comprehensive phenotyping, including assessments of habitual physical activity, dietary intake, glucose tolerance, and whole-body insulin sensitivity. This will allow the researchers to categorize sub-phenotypes of insulin resistance at both the physiological and molecular level.
Following baseline testing, 40 of the 80 participants will undergo one of two short-term interventions designed to stress metabolic pathways associated with insulin sensitivity:
- Reduced physical activity: Participants will significantly decrease their daily physical activity for 14 days.
- High-fat diet: Participants will consume a hypercaloric high-fat diet for 3 consecutive days.
The aim of these interventions is to test how short-term negative lifestyle changes impact insulin action and related molecular markers, and whether these responses vary between individuals with different phenotypic and genetic profiles.
After the intervention period, selected metabolic tests will be repeated to assess changes in insulin sensitivity and molecular signaling. The primary outcome measure is whole-body insulin action, assessed using gold-standard physiological methods. Exploratory outcomes include identifying cellular and molecular mechanisms contributing to insulin resistance, and understanding the interaction between gene expression and lifestyle responses.
By combining deep phenotyping with short-term interventions, this study will generate new insights into the biological diversity of insulin resistance. Ultimately, this may contribute to the development of more individualized strategies for the prevention and treatment of metabolic diseases.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study uses a parallel design involving 80 healthy participants who all undergo comprehensive baseline assessments, including physiological and metabolic phenotyping, habitual physical activity, and dietary intake evaluations. Following baseline characterization, 40 participants are assigned to one of two independent intervention arms: 14 days of reduced physical activity or 3 days of a hypercaloric high-fat diet. Each intervention group is studied in parallel, with outcomes compared to assess the specific effects on insulin sensitivity and molecular mechanisms. The parallel design was chosen due to the invasive and time-intensive nature of the interventions and testing procedures, making a crossover design impractical and burdensome for participants.
| Arm | Type | Receives |
|---|---|---|
| Baseline Characterization | No intervention | –All participants (N=80) undergo extensive baseline characterization over three study visits. This includes assessments of insulin sensitivity, glucose tolerance, metabolic and physiological phenotyping, habitual physical activity, and dietary intake. No intervention is applied during this phase; the purpose is to establish baseline measures and characterize individual variation in insulin resistance and metabolic profiles. Participants complete detailed clinical, physiological, and behavioral assessments without any experimental manipulation. This includes: * Measurement of insulin action and glucose tolerance * Dietary and physical activity profiling * Collection of biospecimens for molecular analyses |
| Lifestyle Interventions | Experimental | Behavioral: Physical Inactivity, Behavioral: Hypercaloric High-Fat DietA subset of 40 participants are randomized into one of two experimental interventions following baseline assessment: * 14 days of reduced physical activity (<1,500 steps/day), or * 3 days of a hypercaloric high-fat diet The aim is to evaluate how short-term lifestyle stressors affect insulin sensitivity and related molecular markers. Assessments from visits 4 and 5 are compared to baseline to determine within-subject changes. Intervention Names: 1. Reduced Physical Activity - Participants limit daily steps to <1,500 for 14 days 2. High-Fat Diet * Participants consume a hypercaloric, high-fat diet for 3 days Description of Intervention: Participants undergo one of the two lifestyle interventions with strict monitoring and support. Selected baseline tests are repeated post-intervention to evaluate metabolic and molecular responses. |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age: 25-55 years
- Body Mass Index (BMI): 18-30 kg/m²
- Healthy (no diagnosed chronic diseases)
- Able and willing to comply with study procedures
Key exclusion criteria (10 listed)
- Smoking or nicotine use, current or within the past 5 years
- Alcohol intake exceeding 10 units per week
- Hemoglobin A1c (HbA1c) > 48 mmol/mol (indicative of diabetes or prediabetes)
- Chronic diseases (e.g., cardiovascular disease, diabetes, etc.)
- Chronic medication use, including hormonal treatments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Physical InactivityAlso: Reduced ActivityParticipants assigned to the physical inactivity intervention will reduce their daily physical activity to fewer than 1,500 steps per day for 14 consecutive days. This strict limitation significantly decreases overall movement and muscle activity, mimicking a sedentary lifestyle. The aim is to assess the short-term effects of reduced physical activity on insulin sensitivity and related metabolic processes. Compliance will be monitored using activity trackers and daily logs. Baseline metabolic and physiological assessments will be repeated after the intervention to evaluate changes. | Behavioural | Lifestyle Interventions |
| Hypercaloric High-Fat DietAlso: OvereatingParticipants assigned to the high-fat diet intervention will consume a hypercaloric diet rich in fat for 3 consecutive days. The diet is designed to significantly increase caloric intake and fat consumption beyond habitual levels to induce short-term metabolic stress. This intervention aims to assess how a brief period of high-fat overfeeding affects insulin sensitivity and related molecular pathways. Participants' dietary intake will be carefully controlled and monitored to ensure adherence. Baseline metabolic and physiological assessments will be repeated after the intervention to evaluate changes. | Behavioural | Lifestyle Interventions |
Primary outcome
Whole-body insulin action
Time frame: Baseline characterization & immediately following intervention (either 14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Glucose disposal rates during hyperinsulinemic euglycemic conditions as a marker of whole-body insulin action
3 secondary outcomes
Identification of proteins and posttranslational modification of proteins in blood as well as skeletal muscle and adipose tissue biopsies
Time frame: Baseline & immediately following the intervention (14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Whole-Body Glucose Tolerance
Time frame: Baseline
Beta Cell Function
Time frame: Baseline & immediately following the intervention (14 days of physical inactivity or 3 days of hypercaloric high-fat diet)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: No. Due to the sensitive nature of the physiological and molecular data collected, and the relatively small and deeply phenotyped cohort, there is a risk of re-identification. Participants have not provided explicit consent for public sharing of their individual data. Furthermore, data protection regulations under the EU General Data Protection Regulation (GDPR) place strict limitations on the sharing of personal data, particularly when it concerns health-related information. For these reasons, individual participant data will not be shared publicly. Data sharing may be considered in the future under controlled access with appropriate ethical approvals and data use agreements.
Related trials for Metabolic Health
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
SweetSpot - The Effect of Non-nutritive Sweeteners on Health
Healthy Adult
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jørgen F.P. Wojtaszewski, Ph.D. principal investigator
University of Copenhagen
Ylva Hellsten, Ph.D. principal investigator
University of Copenhagen
Henriette Pilegaard, Ph.D. principal investigator
University of Copenhagen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Physical Inactivity and Hypercaloric High-Fat Diet in people with Metabolic Health and Insulin Sensitivity/Resistance, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jørgen F.P. Wojtaszewski, Ph.D. (+45 28751625, jw@nexs.ku.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Whole-body insulin action (time frame: Baseline characterization & immediately following intervention (either 14 days of physical inactivity or 3 days of hypercaloric high-fat diet)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.